Hormone therapy using selective oestrogen receptor modular (SERMs) or selective oestrogen receptor degraders (SERDs) is the first line treatment for ER + breast cancers, however combination with CDK4/6 inhibitor (i.e. Palbociclib) has significantly improved clinical outcome of advanced BC patients54,55. This evidence concerns the gene CDK4 and breast cancer.